Lake Street Private Wealth LLC Purchases New Position in Moderna, Inc. (NASDAQ:MRNA)

Lake Street Private Wealth LLC purchased a new stake in Moderna, Inc. (NASDAQ:MRNA) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 2,241 shares of the company’s stock, valued at approximately $239,000.

Several other institutional investors and hedge funds have also recently modified their holdings of MRNA. Allworth Financial LP lifted its holdings in Moderna by 6.5% in the fourth quarter. Allworth Financial LP now owns 1,660 shares of the company’s stock valued at $165,000 after acquiring an additional 101 shares during the last quarter. TIAA Trust National Association raised its position in Moderna by 2.3% in the fourth quarter. TIAA Trust National Association now owns 4,491 shares of the company’s stock valued at $447,000 after purchasing an additional 102 shares during the period. Sound Income Strategies LLC raised its position in Moderna by 17.8% in the fourth quarter. Sound Income Strategies LLC now owns 762 shares of the company’s stock valued at $76,000 after purchasing an additional 115 shares during the period. EverSource Wealth Advisors LLC raised its position in Moderna by 32.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 475 shares of the company’s stock valued at $47,000 after purchasing an additional 116 shares during the period. Finally, Mayfair Advisory Group LLC raised its position in Moderna by 6.0% in the first quarter. Mayfair Advisory Group LLC now owns 2,164 shares of the company’s stock valued at $231,000 after purchasing an additional 122 shares during the period. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Insider Activity at Moderna

In other Moderna news, CFO James M. Mock sold 705 shares of the firm’s stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $101.93, for a total transaction of $71,860.65. Following the transaction, the chief financial officer now owns 5,048 shares of the company’s stock, valued at $514,542.64. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Moderna news, President Stephen Hoge sold 15,000 shares of the firm’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $105.02, for a total transaction of $1,575,300.00. Following the transaction, the president now owns 1,486,241 shares of the company’s stock, valued at $156,085,029.82. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO James M. Mock sold 705 shares of the firm’s stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $101.93, for a total value of $71,860.65. Following the transaction, the chief financial officer now directly owns 5,048 shares in the company, valued at approximately $514,542.64. The disclosure for this sale can be found here. Insiders sold a total of 396,255 shares of company stock valued at $54,593,731 over the last ninety days. Insiders own 15.20% of the company’s stock.

Analyst Upgrades and Downgrades

MRNA has been the topic of a number of research analyst reports. Royal Bank of Canada boosted their target price on Moderna from $135.00 to $160.00 and gave the company an “outperform” rating in a research report on Monday, June 3rd. Oppenheimer boosted their target price on Moderna from $163.00 to $179.00 and gave the company an “outperform” rating in a research report on Wednesday, June 12th. UBS Group boosted their target price on Moderna from $143.00 to $151.00 and gave the company a “buy” rating in a research report on Tuesday, May 7th. Canaccord Genuity Group upped their price objective on Moderna from $91.00 to $106.00 and gave the stock a “hold” rating in a research report on Friday, May 3rd. Finally, Evercore ISI reaffirmed an “in-line” rating and set a $120.00 price objective on shares of Moderna in a research report on Thursday, June 27th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, Moderna currently has a consensus rating of “Hold” and an average target price of $134.02.

Moderna Stock Performance

MRNA stock opened at $115.95 on Friday. Moderna, Inc. has a fifty-two week low of $62.55 and a fifty-two week high of $170.47. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.91 and a current ratio of 4.03. The business has a 50 day moving average price of $134.88 and a 200 day moving average price of $112.67.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, May 2nd. The company reported ($3.07) earnings per share for the quarter, topping the consensus estimate of ($3.59) by $0.52. The business had revenue of $167.00 million during the quarter, compared to the consensus estimate of $93.26 million. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The company’s revenue was down 91.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.19 EPS. As a group, research analysts predict that Moderna, Inc. will post -7.46 EPS for the current fiscal year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.